Phylogica, Cubist make pact to evaluate antimicrobial peptides; Top 25 biotechs of all time;

@FierceBiotech: ICYMI: Sanofi returns to the crowdsourcing well for diabetes app. Article | Follow @FierceBiotech

@RyanMFierce: Stem cell pioneer's biotech startup raises $46M in IPO. Report | Follow @RyanMFierce

@EmilyMFierce: Inovio Pharma DNA cancer vaccine causes tumor death in animals. Article | Follow @EmilyMFierce

> Australian drug discovery company Phylogica has partnered with Cubist Pharmaceuticals ($CBST) to evaluate several of its antimicrobial Phylomers in models of multidrug-resistant bacterial infections. Release

> Genetic Engineering & Biotechnology News has named the top 25 biotech companies of all time. List

> Frankfurt, Germany-based biotech 4SC ($VSC) is beginning a Phase I/II study with cancer compound resminostat in non-small-cell lung cancer in Japan with Japanese partner Yakult Honsha. Release

Pharma News

@FiercePharma: FTC eyeing new patent deals for pay-for-delay action in wake of SCOTUS ruling. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: Wednesday at Fierce, starring Neuron, Measles, Tuberculosis, MRSA and E. coli. Image | Follow @CarlyHFierce

> Roche's 'blowout' cancer launches help fuel 10% profits hike. Story

> GlaxoSmithKline to pay states $229M to wrap Avandia suits, other claims. Article

> Biogen's Tecfidera races past estimates with $192M in Q2 sales. Report

Medical Device News

@FierceMedDev: Boston Scientific's Q2 reflects both stagnation and promising growth. Article | Follow @FierceMedDev

@MarkHFierce: We are entering our last week for FMD F15 nominations. Get yours in now. Submission form | Follow @MarkHFierce

@DamianFierce: Roche posted only slight diagnostics growth in H1, as a diabetes slump weighed down testing sales. Story | Follow @DamianFierce

 @MichaelGFierce: From FierceDrugDelivery.com: Novaliq secures CE mark for OTC drop to treat dry eye. Report | Follow @MichaelGFierce

> Abbott wins FDA nod for glucose monitor. More

> Blood Dx to predict sepsis-related death may be within reach. Item

> Abbott slashes 200 more jobs from CA stent operation. Report

Pharma Manufacturing News

@EricPFierce: CMO Exela looks to get $1 million USDA loan to help expand plant, add jobs. Story | Follow @EricPFierce

> Fresenius Kabi Indian plant accused of manipulating data. More

> Lonza phasing out troubled Massachusetts biologics plant. Report

> FMC spends $345M for Epax omega-3 plants. Item

> FDA excoriates Wockhardt over missing records, standing urine. Story

> GSK looks to manufacturing to reduce vaccine costs. Article

Vaccines News

> Indian ethics journal pushes for ban on Crucell vaccine. Item

> Serum targets Merck, Sanofi stronghold with TB vax deal. More

> U.K. rejection of Bexsero hits Novartis vaccine unit. Report

> Lupin eyes vaccine growth after in-licensing Merck shot. News

> GSK planning joint venture to tap into Chinese vaccine demand. Article

> Study suggests GSK's Cervarix can prevent throat cancer. Story

And Finally... Odile Rundquist, senior analyst at Helvea, previews quarterly results from GlaxoSmithKline ($GSK). Video

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.